Principal Financial Group
EIGR

Principal Financial Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Principal Financial Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-450
Closed -$12.1K – 2526
2023
Q1 		$12.1K Sell
450
-19
-4% -$884 ﹤0.01% 2440
2022
Q4 		$16.6K Buy
+469
New +$56.3K ﹤0.01% 2409

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Principal Financial Group's EIGR Position: Q2 2023 in Review

Principal Financial Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 450 shares — an estimated $12.1K sold.

Principal Financial Group first reported a position in EIGR in Q4 2022 and held it in 2 quarters. The position peaked at $16.6K in Q4 2022. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

  • Principal Financial Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Principal Financial Group sold 450 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $12.1K.
  • Principal Financial Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
  • Principal Financial Group's Eiger BioPharmaceuticals, Inc. position peaked at $16.6K in Q4 2022.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Principal Financial Group's 13F filing for Q2 2023, filed 7 Aug 2023.